Glycobance Tablet 500/5 mg

Adult dose

The standard starting dose is 500 mg of Metformin Hydrochloride/Glibenclamide 2.5 mg, taken as 1 tablet daily. For patients receiving both Metformin Hydrochloride and Glibenclamide, the dose is 2 tablets daily with meals. The dose may be increased gradually by 1 tablet every 1-2 weeks according to blood sugar levels, with the maximum dose being 500 mg of Metformin Hydrochloride/Glibenclamide 5 mg, up to 4 tablets daily.

This medication can cause severe lactic acidosis and hypoglycemia, so it should not be administered to patients with impaired kidney function or those in acute conditions such as acute infections or myocardial infarction. Additionally, this medication is associated with an increased risk of cardiovascular mortality, requiring caution in patients with a history of heart failure or myocardial infarction. Patients with reduced kidney function, impaired liver function, pregnant or breastfeeding women, and those taking certain medications should not use this medication or should use it with caution. During treatment, patients should be vigilant for signs of hypoglycemia, which may include cold sweats, dizziness, headaches, palpitations, and hunger. Due to the risk of lactic acidosis, patients experiencing dehydration, severe infections, or hypoxia should immediately discontinue the medication and seek medical attention. Gastrointestinal side effects (abdominal pain, diarrhea, nausea, vomiting, etc.) are common and can be minimized by gradually increasing the dosage or dividing the doses with meals. Regular blood tests to monitor kidney function, liver function, and vitamin B12 levels are necessary to ensure there are no abnormalities. There may be interactions with other medications; therefore, it is essential to inform a physician or pharmacist if any other medications are being used. Overdose can result in hypoglycemia or lactic acidosis, necessitating immediate treatment in a hospital setting if consciousness is impaired. Caution should be exercised when driving or operating machinery if there is blurred vision or symptoms of hypoglycemia, and such activities should be avoided if symptoms are severe. Lastly, this medication should be kept out of reach of children, and it should not be used by women who are pregnant or may become pregnant, or by nursing mothers.

Serious side effects

Severe lactic acidosis, hypoglycemia (cold sweats, pallor, coma, seizures, etc.), increased risk of cardiovascular mortality, serious allergic reactions (hives, severe swelling, chest tightness, difficulty breathing), severe skin reactions (severe rashes with fever, blisters, skin peeling, mucosal pain), respiratory problems (shortness of breath or difficulty breathing, asthma attacks, cough accompanied by fever), liver abnormalities (jaundice of the skin and eyes, systemic issues)

Mild side effects

Gastrointestinal symptoms (upper abdominal pain, diarrhea, nausea, vomiting, abdominal pain, loss of appetite), certain sensory disturbances (unpleasant metallic taste), skin reactions (itchiness, urticaria, papular rash, allergic vasculitis, erythema multiforme, dermatitis, photosensitivity), hematological abnormalities (leukopenia, thrombocytopenia, agranulocytosis, hemolytic anemia, aplastic bone marrow, pancytopenia), vitamin B12 deficiency, elevated liver enzymes, hepatic and skin toxicity

This medication may be sensitive to air and moisture; therefore, it should be stored in a tightly sealed container. Additionally, it is advisable to store the medication at room temperature between 1 to 30 degrees Celsius, avoiding excessively hot or cold environments. Proper storage will help maintain the medication's efficacy for a longer period.

Appearance

Pale yellow, oval-shaped, film-coated tablets with convex surfaces on both sides

Package unit

For domestic use - 60 tablets/box [(20 tablets/PTP packaging x 3)]